Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 6.95 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: povidone; pregelatinised maize starch; silicified microcrystalline cellulose; lactose monohydrate; magnesium stearate; isopropyl alcohol; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/5/25 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.9 mg; hydrochlorothiazide, quantity: 25 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; silicified microcrystalline cellulose; povidone; lactose monohydrate; pregelatinised maize starch; magnesium stearate; titanium dioxide; purified talc; iron oxide red; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/10/25 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 6.95 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; pregelatinised maize starch; magnesium stearate; povidone; lactose monohydrate; silicified microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/5/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.9 mg; hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; povidone; pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; titanium dioxide; purified talc; iron oxide red; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/10/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; amlodipine besilate, quantity: 6.95 mg; olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; magnesium stearate; lactose monohydrate; povidone; titanium dioxide; purified talc; iron oxide red; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - apo-olmesartan/amlodipine/hctz 20/5/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 25 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: microcrystalline cellulose; sodium hydroxide; maize starch; magnesium stearate; povidone; sodium starch glycollate type a; lactose monohydrate; meglumine; mannitol; iron oxide yellow - telmisartan hct mylan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - hydrochlorothiazide, quantity: 25 mg; candesartan cilexetil, quantity: 32 mg - tablet - excipient ingredients: carrageenan; povidone; lactose monohydrate; magnesium stearate; croscarmellose sodium; iron oxide black; titanium dioxide; maize starch; iron oxide red - the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); valsartan, quantity: 160 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide yellow - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - captopril; hydrochlorothiazide - tablet - 50/25mg milligram(s) - ace inhibitors and diuretics; captopril and diuretics

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - candesartan cilexetil, quantity: 32 mg; hydrochlorothiazide, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; carmellose calcium; macrogol 8000; hyprolose; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.